Compliance with Pregnancy Prevention Recommendations for Isotretinoin in Estonia in 2012–2016

• Published in: Drugs - real world outcomes Vol. 5; no. 2; pp. 129 - 136
• Main Authors: Uusküla, Anneli, Pisarev, Heti, Kurvits, Katrin, Laius, Ott, Laanpere, Made, Uusküla, Maia
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.06.2018; Springer Nature B.V
• Subjects: Abortion; Acne; Birth control; Codes; Contraindications; Disease prevention; Drug therapy; Females; Internal Medicine; Medicine; Medicine & Public Health; Original; Original Research Article; Patient compliance; Pharmacology/Toxicology; Pharmacotherapy; Pregnancy; Prescriptions; Transplants & implants; Vagina; Womens health; Estonia
• ISSN: 2199-1154; 2198-9788
• DOI: 10.1007/s40801-018-0135-z

Background Isotretinoin is an effective treatment for severe acne; no alternative treatment has an equal therapeutic effect. The teratogenic effects of isotretinoin can be avoided, and numerous recommendations and regulations are in force to minimize the risk of pregnancy during treatment. Objectives To describe isotretinoin prescription patterns for women aged 15–45 years, assess the concomitancy of isotretinoin and contraceptive use, and determine the rate of potential isotretinoin-exposed pregnancies in Estonia. Methods This retrospective, nationwide, population-based, cohort study derived data from national health insurance databases and included female patients aged 15–45 years in Estonia for whom one or more prescriptions for isotretinoin were dispensed between 2012 and 2016. The main outcome was the proportion of women who used systemic isotretinoin and had a concomitant record of (hormonal or intrauterine) contraception use covering the isotretinoin treatment period when pregnancy is contraindicated. Results Of the 2792 women aged 15–45 years filling an isotretinoin prescription, 15.7% (95% CI 14.4–17.1) had full and 13.9% (95% CI 12.7–15.3) partial (not covering the whole period during which pregnancy is contraindicated) contraceptive coverage. The risk for potential isotretinoin-exposed pregnancy was 3.6 (95% CI 2.0–7.0) per 1000 treated women over the 5-year observation period. The odds for full coverage with effective contraception increased with the age of the patient, with the duration of isotretinoin treatment and over the period of observation. Conclusion Our study adds to the existing literature documenting limited compliance with pregnancy prevention programs for isotretinoin-containing products, and calls for program assessment to identify whether new measures should be taken or whether weaknesses in policy or implementation can be corrected.